Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over an 8-week Treatment Period in Adult Subjects With Atopic Dermatitis.

NCT03725722 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

251

Enrollment

INDUSTRY

Sponsor class

Conditions

Atopic Dermatitis

Interventions

DRUG: Delgocitinib cream
DRUG: Delgocitinib cream vehicle

Sponsor

LEO Pharma